Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...

ShareThe World Health Organisation (WHO) is assembling a Guideline Development Group (GDG) to craft recommendations for the ...

A milestone was reached in the fight against HIV/AIDS with the development of Lenacapavir, a new injectable drug that ...

A Gilead representative received a standing ovation at AIDS24, held in July in Munich, Germany, after unveiling data from the PURPOSE 1 trial (NCT04994509) of lenacapavir for HIV PReP. In a Phase ...

A Gilead representative received a standing ovation at AIDS24, held in July in Munich, Germany, after unveiling data from the PURPOSE 1 trial (NCT04994509) of lenacapavir for HIV PReP. Tick here to ...

Science magazine has chosen twice-yearly lenacapavir PrEP as its 2024 Breakthrough of the Year, recognizing it as a game-changer in the fight to end the global HIV epidemic. Looking ahead, once-yearly ...

The ambition is to start deliveries of Gilead Sciences’ lenacapavir on that timeline, said Hui Yang, head of supply operations at the Global Fund to Fight AIDS, Tuberculosis and Malaria.